JP Morgan Private Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,090	Closed	-$218K	–	1481
2023 Q1	$218K	Buy	+1,090	New	+$229K	﹤0.01%	1798
2022 Q4	–	Sell	-1,135	Closed	-$227K	–	1924
2022 Q3	$227K	Buy	+1,135	New	+$216K	﹤0.01%	1759
2020 Q4	–	Sell	-37,922	Closed	-$5.52M	–	1703
2020 Q3	$5.52M	Buy	37,922 +35,850	+1,730%	+$5.09M	0.02%	409
2020 Q2	$307K	Buy	+2,072	New	+$279K	﹤0.01%	1295
2018 Q3	–	Sell	-2,336	Closed	-$230K	–	1573
2018 Q2	$230K	Buy	+2,336	New	+$232K	﹤0.01%	1303

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

JP Morgan Private Wealth Advisors's ALNY Position: Q2 2023 in Review

JP Morgan Private Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 1,090 shares — an estimated $218K sold.

JP Morgan Private Wealth Advisors first reported a position in ALNY in Q2 2018 and held it in 5 quarters. The position peaked at $5.52M in Q3 2020. 477 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

JP Morgan Private Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 1,090 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $218K.
JP Morgan Private Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 5 quarters.
JP Morgan Private Wealth Advisors's Alnylam Pharmaceuticals position peaked at $5.52M in Q3 2020.
477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.